Detalhe da pesquisa
1.
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
Value Health
; 26(10): 1543-1548, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37422075
2.
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
Oncologist
; 25(12): 1067-1074, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026700
3.
[Combination therapies in immuno-oncology: differentiated regulatory approaches]. / Kombinationstherapien in der Immunonkologie: Differenzierte regulatorische Herangehensweisen.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
; 63(11): 1388-1395, 2020 Nov.
Artigo
em Alemão
| MEDLINE | ID: mdl-33084926
4.
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Oncologist
; 24(5): e171-e179, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30898889
5.
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Oncologist
; 23(5): 594-602, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29371479
6.
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Pharmacoepidemiol Drug Saf
; 23(7): 667-78, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24821575
7.
Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia.
Drug Discov Today
; 27(9): 2440-2466, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35597514
8.
The changing landscape of treatment options in childhood acute lymphoblastic leukaemia.
Drug Discov Today
; 27(5): 1483-1494, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007767
9.
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Hemasphere
; 5(12): e666, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34805769
10.
The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac.
Pharmacoepidemiol Drug Saf
; 23(4): 431-4, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24616204
11.
[Approval of new medicinal products - administrative procedures].
Ugeskr Laeger
; 181(21)2019 May 20.
Artigo
em Dinamarquês
| MEDLINE | ID: mdl-31124440
12.
[Approval of new medicinal products - documentation requirements].
Ugeskr Laeger
; 181(21)2019 May 20.
Artigo
em Dinamarquês
| MEDLINE | ID: mdl-31124441
13.
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
ESMO Open
; 4(5): e000570, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31555488
14.
Progression-free survival (PFS) in oncology: caveat emptor!
Basic Clin Pharmacol Toxicol
; 124(3): 237-238, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30672131
15.
Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Basic Clin Pharmacol Toxicol
; 111(3): 189-97, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22448752
16.
A comprehensive approach to benefit-risk assessment in drug development.
Basic Clin Pharmacol Toxicol
; 111(1): 65-72, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22356197
17.
Excitatory amino acid transporters EAAT-1 and EAAT-2 in temporal lobe and hippocampus in intractable temporal lobe epilepsy.
APMIS
; 117(4): 291-301, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19338517